World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
48826
World Ranking
7546
National Ranking
3938

John A. Glaspy publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John A. Glaspy sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 420 publications — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John A. Glaspy D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John A. Glaspy sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 102 D-Index — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

John A. Glaspy is a researcher affiliated with the University of California, Los Angeles in the United States. Their body of work predominantly falls within the field of Medicine, with a significant focus on Oncology, Genetics, and Hematology. Glaspy's research intersects with both clinical and public health domains, addressing complex issues in cancer treatment, blood disorders, and health economics.

Their recent publications demonstrate a range of topics, including cancer immunotherapy, anemia treatment, and chemotherapy complications. Notable papers include:

  • "Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)," published in 2021 in Neuro-Oncology
  • "Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?" published in 2022 in The Oncologist
  • "Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review," published in 2020 in Therapeutics and Clinical Risk Management
  • "Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial," published in 2023 in Journal for ImmunoTherapy of Cancer
  • "Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer," published in 2020 in ESMO Open

Frequent coauthors collaborating with Glaspy include:

  • Sidharth Anand
  • Anne M. Walling
  • Dennis J. Slamon
  • Martina S.J. McDermott
  • Neil A. O'Brien

Glaspy has contributed extensively to several prominent publication venues, with multiple papers appearing in:

  • Journal of Clinical Oncology
  • Cancer Research
  • JCO Oncology Practice
  • Clinical Cancer Research
  • American Journal of Hematology

Their research topics cover a broad spectrum related to cancer and blood disorders. Key themes include:

  • Economic and Financial Impacts of Cancer
  • Erythropoietin and Anemia Treatment
  • Cancer Immunotherapy and Biomarkers
  • Blood disorders and treatments
  • Hemoglobinopathies and Related Disorders
  • Neutropenia and Cancer Infections
  • CAR-T cell therapy research

John A. Glaspy's interdisciplinary work integrates clinical oncology with health economics and public health considerations, reflecting a multifaceted approach to disease management and treatment advancement.

Best Publications

  • PD-1 blockade induces responses by inhibiting adaptive immune resistance

    Paul C. Tumeh;Christina L. Harview;Jennifer H. Yearley;I. Peter Shintaku

  • Adjuvant trastuzumab in HER2-positive breast cancer.

    Dennis Slamon;Wolfgang Eiermann;Nicholas Robert;Tadeusz Pienkowski

  • Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

    Jeffrey Crawford;Howard Ozer;Ronald Stoller;David H Johnson

  • Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

    Mark D. Pegram;Allen Lipton;Daniel F. Hayes;Barbara L. Weber

  • RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky

  • Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

    Hubing Shi;Willy Hugo;Xiangju Kong;Aayoung Hong

  • Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

    John Glaspy;Ronald Bukowski;David Steinberg;Charles Taylor

  • Thrombocytopenia caused by the development of antibodies to thrombopoietin.

    Junzhi Li;Chun Yang;Yuping Xia;Amy Bertino

  • Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion

    Dilprit Bagga;Ling Wang;Robin Farias-Eisner;John A. Glaspy

  • Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

    Neil N. Senzer;Howard L. Kaufman;Thomas Amatruda;Mike Nemunaitis

  • Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

    Jason Chesney;Igor Puzanov;Frances Collichio;Parminder Singh

  • Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer

    F.A. Holmes;J.A. O’Shaughnessy;S. Vukelja;S.E. Jones

  • Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

    Antoni Ribas;Luis H. Camacho;Gabriel Lopez-Berestein;Dmitri Pavlov

  • Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy

    Jeffrey Crawford;David Cella;Charles S. Cleeland;Pierre Yves Cremieux;Pierre Yves Cremieux

  • A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia

    DC Dale;MA Bonilla;MW Davis;AM Nakanishi

  • A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides

    Lisa H. Butterfield;Antoni Ribas;Vivian B. Dissette;Yohan Lee

  • Electroacupuncture for Control of Myeloablative Chemotherapy–Induced Emesis: A Randomized Controlled Trial

    Joannie Shen;Neil S. Wenger;John Glaspy;Ron D. Hays

  • Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells.

    Ronald L. Paquette;Nicholas C. Hsu;Sylvia M. Kiertscher;Alice N. Park

  • Current Developments in Cancer Vaccines and Cellular Immunotherapy

    Antoni Ribas;Lisa H. Butterfield;John A. Glaspy;James S. Economou

  • A comparison of gene transfer methods in human dendritic cells

    J F Arthur;L H Butterfield;M D Roth;L A Bui

Frequent Co-Authors

Antoni Ribas
Antoni Ribas University of California, Los Angeles
James S. Economou
James S. Economou University of California, Los Angeles
William H. McBride
William H. McBride University of California, Los Angeles
Lisa H. Butterfield
Lisa H. Butterfield University of California, San Francisco
Jeffrey Crawford
Jeffrey Crawford Duke University
Neil S. Wenger
Neil S. Wenger University of California, Los Angeles
Heinz Ludwig
Heinz Ludwig University of Vienna
Carl K. Hoh
Carl K. Hoh University of California, San Diego
Véronique Diéras
Véronique Diéras Institute Curie
Michael E. Phelps
Michael E. Phelps University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine opens up diverse and flexible study options. Many students consider online degrees to help balance education with personal and work commitments. For those interested in supporting healthcare operations, taking billing and coding classes online can be an affordable and quick way to enter the healthcare field.

Aspiring nurses have several online pathways as well. There are affordable nursing programs online that make nursing education accessible without the high costs of traditional programs. For advanced roles, like becoming a nurse practitioner, students often look for the cheapest fnp programs to minimize student debt while advancing their careers and earning potential.

For those aiming for leadership or research positions, pursuing a phd nursing education online offers the flexibility to work and study simultaneously. With these options, students can find a pathway that suits their goals, learning style, and budget—making healthcare education more accessible than ever.

Best Scientists Citing John A. Glaspy

Trending Scientists

Recently Published Articles